Absolute Day Trader Picks

media-crush-logo_thumb

Featured on Media Crush

Absolute Day Trader Picks was recently a featured post on Media Crush!

Many months ago ADTP Frank Magliochetti chose OPKO Health Inc as a featured company to watch.

Lo and behold the pick has been a hot one with OPKO Health Inc heating up many of the trend setting stock analysts sites.

CLICK HERE to take a look at what our marketing company had to say recently on their blog about ADTP.

 

Media Crush LLC

OPKO to List on Tel Aviv for Prolor Deal

Tel Aviv Stock Exchange

Billionaire Phillip  Frost to List Shares…

Tel Aviv Stock ExchangeOpko Health Inc. (OPK:US), led by billionaire Phillip Frost, is set to list shares on the Tel Aviv Stock Exchange as it seeks to complete the acquisition of Israeli drugmaker Prolor Biotech Inc. (PBTH:US)

 

OPKO Health IncShares of the Miami-based drug developer, which are already listed on the New York Stock Exchange, will begin trading in Tel Aviv on Aug. 21, a bourse spokeswoman said by telephone today. In October, the stock will enter the Tel Aviv 25 Index (TA-25), a gauge of the exchange’s largest companies by market value, she said.

Prolor-Biotech_OPKOOpko’s listing would enable it to pay Prolor shareholders in locally listed stock. The deal announced in April gave them 0.9951 Opko shares for each stock in Prolor. While the share swap valued Prolor at $480 million in April, a 12 percent increase in Opko’s shares since then has boosted the value to about $540 million.

Prolor’s stock, which will be delisted, has gained 27 percent since the deal was announced. The transaction is expected to close in the second half of this year, provided Opko and Prolor shareholders approve the merger in a vote on Aug. 28.

After selling Ivax Corp. to Teva (TEVA) for $7.4 billion in 2006, Frost and his associates began assembling Opko, a health-care holding company for diagnostic equipment and medical products. Frost is the chairman and largest shareholder in both Opko and Prolor and one of Prolor’s early investors. He’s also chairman of Teva.

Sourced From:
http://www.businessweek.com/news/2013-08-19/billionaire-frost-s-opko-to-list-in-tel-aviv-for-prolor-deal
by David Wainer in Tel Aviv – Bloomberg

About Absolute Day Trader Picks

This is a site sponsored and driven by content supplied and aggregated  by Frank Magliochetti and Parcae Capital Corporation.  It will highlight emerging growth companies and picks made by Frank Magliochetti and his team of professionals.

If you have a company interested in having our team review for our Day Trading Pick please contact us by clicking here.

Day Trader Picks

OPKO Rayaldy News:

OPKO Health Inc

Surpasses 50% enrollment in second phase III trials

OPKO Health IncOPKO Health, Inc. has surpassed 50 per cent enrollment in the second phase III trial of Rayaldy to treat patients with secondary hyperparathyroidism (SHPT), stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency. This trial is the second of two identical randomized, double-blind, placebo controlled, multi-site studies intended to establish the safety and efficacy of Rayaldy as a new treatment for SHPT in the targeted population.

The endpoints of both studies, which are being conducted in parallel, include vitamin D status and changes in serum calcium, serum phosphorus and plasma intact parathyroid hormone (PTH).

Each of the two phase III trials will involve 210 patients recruited at approximately 40 sites in the US. These patients are being stratified by CKD stage and randomized in a 2:1 fashion to receive six months of treatment with either Rayaldy or placebo. Dosing with Rayaldy is titrated, as necessary, to achieve the desired blood concentration and the targeted reduction in PTH.

“I am pleased to report that these pivotal trials with Rayaldy Capsules are progressing as planned toward completion in the first half of 2014,” stated Phillip Frost, MD, OPKO’s chairman and chief executive officer. “Top-line data are expected in mid-2014. We believe Rayaldy will prove to be superior to high monthly doses of prescription vitamin D2, a common therapeutic approach which has been shown unreliable in correcting vitamin D insufficiency in patients with chronic kidney disease and generally ineffective in controlling elevated levels of parathyroid hormone. We look forward to advancing the standard of care for this patient population when Rayaldy is ultimately approved for marketing.”

Rayaldy is a first-in-class oral vitamin D prohormone treatment being developed for SHPT in stage 3 and 4 CKD patients with vitamin D insufficiency. It has a proprietary modified-release formulation designed to gradually and reliably raise serum total 25-hydroxyvitamin D (prohormone) concentrations to targeted levels (at least 30 ng/mL) while avoiding upregulation of CYP24, a cytochrome P-450 enzyme that reduces the PTH lowering potency of current vitamin D supplements. Activation of the product by the kidney is tightly regulated, preventing excessive elevation of serum calcium and related side effects which encumber current vitamin D hormone therapies and promote vascular and renal calcification. Once approved, Rayaldy will address the approximately four million CKD stage 3 and 4 patients in the US and many more, elsewhere, with SHPT and vitamin D insufficiency.

CKD is a condition characterized by a progressive decline in kidney function. The kidney is normally responsible for excreting waste and excess water from the body, and for regulating various hormones. CKD is classified in five different stages — mild (stage 1) to severe (stage 5) disease — as measured by the kidney’s glomerular filtration rate.

Vitamin D insufficiency is a condition in which the body has low vitamin D stores, characterized by inadequate blood levels of vitamin D prohormones, collectively known as 25-hydroxyvitamin D.

SHPT is a condition commonly associated with CKD in which the parathyroid glands secrete excessive amounts of PTH. SHPT arises as a result of vitamin D insufficiency or impaired kidney function that prevents sufficient production of vitamin D hormones to properly regulate calcium and phosphorus metabolism, and PTH secretion. Prolonged elevation of blood PTH causes excessive calcium and phosphorus to be released from bone, leading to elevated serum calcium and phosphorus, softening of the bones (osteomalacia) and calcification of vascular and renal tissues.

OPKO is a multi-national biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large and rapidly growing medical markets by leveraging our discovery, development and commercialization expertise and our novel and proprietary technologies.

About Absolute Day Trader Picks

This is a site sponsored and driven by content supplied and aggregated  by Frank Magliochetti and Parcae Capital Corporation.  It will highlight emerging growth companies and picks made by Frank Magliochetti and his team of professionals.

If you have a company interested in having our team review for our Day Trading Pick please contact us by clicking here.

Day Trader Picks

NEWS: Opko Health Inc. Hits New 52-Week High at $8.00

OPKO Health, Inc - Absolute Day Trader Picks

Absolute Day Trader Picks – Pick Hit!

Back in April OPKO it was decided that OPKO was a pick hit company and a stock to watch.

Yesterday, OPKO Health closed at a 52 Week High at $8.00, this almost doubles the year low of $4.05.   

Frank Magliochetti of Absolute Day Trader Picks and managing partner at Parcae Capital has had this on our watch list for quite a while.  

Opko Health (NYSE:OPK) set a new 52-week high during mid-day trading on Thursday, AnalystRatings.Net reports. The stock traded as high as $8.00 and last traded at $7.85, with a volume of 2,225,379 shares. The stock had previously closed at $7.88.

OPK has been the subject of a number of recent research reports. Analysts at Barrington Research raised their price target on shares of Opko Health from $7.50 to $9.00 in a research note to investors on Monday. They now have an “outperform” rating on the stock. Analysts at Ladenburg Thalmann raised their price target on shares of Opko Health from $8.50 to $10.00 in a research note to investors on Thursday, May 30th. They now have a “buy” rating on the stock.

Opko Health has a one year low of $4.05 and a one year high of $8.00. The stock has a 50-day moving average of $7.46 and a 200-day moving average of $7.15. The company’s market cap is $2.644 billion.

 

About OPKO Health, Inc.

OPKO Health, Inc (NYSE:OPK), incorporated in October 1991, is a multi-national biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large and rapidly growing medical markets by leveraging our discovery, development and commercialization expertise and our novel and proprietary technologies.

About Absolute Day Trader Picks

This is a site sponsored and driven by content supplied and aggregated  by Frank Magliochetti and Parcae Capital Corporation.  It will highlight emerging growth companies and picks made by Frank Magliochetti and his team of professionals.

If you have a company interested in having our team review for our Day Trading Pick please contact us by clicking here.

Day Trader Picks

 

OPKO Health, Inc – Merger News

opko-160x160

Dr Phillip Frost can vote on Prolor-Opko merger

absolute day trader picks Frank Magliochetti

Jul 28, 2013  –Dr. Phillip Frost, the chairman of both Prolor Biotech Inc. PBTH(tase:PBTH) and Opko Health Inc.  OPK has the right to vote on the merger of the two companies on August 28, states Prolor in the summons to the general shareholders meeting which will vote on the merger. Each company will hold a separate vote on the merger. Frost is also chairman of Teva Pharmaceutical Industries Ltd. TEVA(tase:TEVA).

Frost is the biggest shareholder in both Prolor and Opko, owning 26.5 percent of the former and 50 percent of the latter. In contrast to Israeli law, under US law, Frost and his associates who are parties at interest in the deal are not banned from voting on it. This means that the vote by Opko shareholders is essentially a done deal. As for Prolor, the parties will have to secure a third of the independent shareholders to approve the merger.

“Although Frost initiated the merger, he was not personally involved in the negotiations, which were managed by a team of external directors of each party. The law therefore allows Frost to vote as an ordinary shareholder,” Prolor president Shai Novik.

The description of the negotiations in the proxy statement, which the companies published for the merger, Frost proposed the merger and the price, which were not changed during the negotiations. Prior to this proposed merger, Prolor was in acquisition talks with Teva, but the parties could not agree on terms.

Prolor has a market cap of 442 million, and Opko has a market cap of 2.5 billion. Under the merger terms of 0.9951 Opko shares for each Prolor share, the deal gives Prolor a share price of 7.64, a 9.6 percent premium on Friday’s closing price of 6.96, and a 30 percent premium on its share price when the merger was announced.

Frost has bought Opko shares since the merger was announced. He bought shares in the company in previous years, but picked up the pace following the announcement, helping boost the share price. This also affected the company value of Prolor for the deal, which will be through a share swap. The purchases also boosted Frost’s stake in Opko to over 50 percent, which means that he can decide the vote on the merger by himself.

At the same time, Frost also bought shares in Prolor. “I am buying Opko because it’s a good investment and Prolor because it’s like buying Opko at a discount,” he says.

In the proxy statement, Opko says that, after the merger with Prolor, it is considering a listing on the Tel Aviv Stock Exchange (TASE). It is a diversified life sciences company with diagnostic and drug development operations, most of which it acquired from third parties. It posted a loss of 34 million on 31 million revenue for the first quarter of 2013, compared with a loss of 8.6 million on 8.7 million for the corresponding quarter of 2012.

Besides Frost, Opko has an Israeli connection through two pharmaceutical manufacturing companies which it acquired for small amounts: Nesher-based FineTech Pharmaceutical Ltd. and Rehovot-based SciGen Israel Ltd.

Prolor is developing delayed-release injectable drugs. Its flagship product is a longer acting human growth hormone, which can be delivered once a week or every other week, instead of daily. The company is about to begin a Phase III clinical trial (multicenter efficacy trial) on the drug.

 

About Prolor Biotech

PROLOR Biotech is developing proprietary versions of already-approved therapeutic proteins. The Company’s Carboxyl Terminal Peptide technology can be attached to an array of existing therapeutic proteins, stabilizing the therapy in the bloodstream and extending its lifespan without additional toxicity or loss of desired biological activity.

PROLOR products under development include Human Growth Hormone (“hGH”) for the long-term treatment of children and adults with growth failure due to inadequate secretion of endogenous growth hormone (a $3 billion market opportunity). PROLOR’s hGH could potentially be injected once a week or twice per month instead of daily. PROLOR’s hGH is scheduled for Phase III trials in 2013.

PROLOR’s GLP-1 / Glucagon dual receptor agonist for Diabetes Type II (a $2 billion market opportunity) could be injected once a week and may have a dramatically better weight-loss profile than current GLP-1 therapies.

PROLOR is also developing Factor VIIa and Factor IX for Hemophilia (a $2 billion market opportunity); Anti-Obesity Peptide Oxyntomodulin; Interferon ß and Erythropoietin; and Atherosclerosis and Rheumatoid Arthritis long-acting therapies.

PROLOR’s offices and research and development facilities are located in Israel in the Weizmann Science Park, Nes-Ziona.

Day Trader Picks

This is a site sponsored and driven by content supplied and aggregated  by Frank Magliochetti and Parcae Capital Corporation.  It will highlight emerging growth companies and picks made by Frank Magliochetti and his team of professionals.

If you have a company interested in having our team review for our Day Trading Pick please contact us by clicking here.

Day Trader Picks